Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.

Röth A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H, Terriou L, Urbano-Ispizua Á, Wells RA, Jang JH, Kulasekararaj AG, Szer J, Aguzzi R, Damokosh AI, Shafner L, Lee JW.

Blood Adv. 2018 Sep 11;2(17):2176-2185. doi: 10.1182/bloodadvances.2018020644.

2.

Sideroblastic anemia with myopathy secondary to novel, pathogenic missense variants in the YARS2 gene.

Smith F, Hopton S, Dallabona C, Gilberti M, Falkous G, Norwood F, Donnini C, Gorman GS, Clark B, Taylor RW, Kulasekararaj AG.

Haematologica. 2018 Jul 5. pii: haematol.2018.194464. doi: 10.3324/haematol.2018.194464. [Epub ahead of print] No abstract available.

3.

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms.

Marsh JCW, Gutierrez-Rodrigues F, Cooper J, Jiang J, Gandhi S, Kajigaya S, Feng X, Ibanez MDPF, Donaires FS, Lopes da Silva JP, Li Z, Das S, Ibanez M, Smith AE, Lea N, Best S, Ireland R, Kulasekararaj AG, McLornan DP, Pagliuca A, Callebaut I, Young NS, Calado RT, Townsley DM, Mufti GJ.

Blood Adv. 2018 Jan 4;2(1):36-48. doi: 10.1182/bloodadvances.2017008110. eCollection 2018 Jan 9.

4.

Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia.

Fattizzo B, Zaninoni A, Gianelli U, Zanella A, Cortelezzi A, Kulasekararaj AG, Barcellini W.

Am J Hematol. 2018 Aug;93(4):E88-E91. doi: 10.1002/ajh.25020. Epub 2018 Jan 10. No abstract available.

PMID:
29274091
5.

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR, Lindeman R, Young B, Ramakrishna R, Arthur C, Stark R, Crispin P, Curnow J, Warburton P, Roncolato F, Boultwood J, Lynch K, Jacobsen SEW, Mufti GJ, Hellstrom-Lindberg E, Wilkins MR, MacKenzie KL, Wong JWH, Campbell PJ, Pimanda JE.

Cell Rep. 2017 Jul 18;20(3):572-585. doi: 10.1016/j.celrep.2017.06.067.

6.

Preclinical modeling of myelodysplastic syndromes.

Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti GJ, Bonnet D.

Leukemia. 2017 Dec;31(12):2702-2708. doi: 10.1038/leu.2017.172. Epub 2017 Jun 2.

7.

Clonal dominance of PNH- another piece to the jigsaw.

Kulasekararaj AG.

Br J Haematol. 2017 Apr;177(1):9-10. doi: 10.1111/bjh.14552. Epub 2017 Mar 14. No abstract available.

PMID:
28295191
8.

Myelodysplastic syndrome can propagate from the multipotent progenitor compartment.

Rouault-Pierre K, Smith AE, Mian SA, Pizzitola I, Kulasekararaj AG, Mufti GJ, Bonnet D.

Haematologica. 2017 Jan;102(1):e7-e10. doi: 10.3324/haematol.2016.152520. Epub 2016 Oct 6. No abstract available.

9.

RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis.

Alkhatabi HA, McLornan DP, Kulasekararaj AG, Malik F, Seidl T, Darling D, Gaken J, Mufti GJ.

Oncotarget. 2016 Jul 26;7(30):47875-47890. doi: 10.18632/oncotarget.10293.

10.

CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.

Smith AE, Kulasekararaj AG, Jiang J, Mian S, Mohamedali A, Gaken J, Ireland R, Czepulkowski B, Best S, Mufti GJ.

Lancet Haematol. 2015 May;2(5):e212-21. doi: 10.1016/S2352-3026(15)00050-2. Epub 2015 May 6.

PMID:
26688096
11.

Sweet spot for cyclophosphamide: a balancing act.

Kulasekararaj AG, Marsh JC.

Lancet Haematol. 2015 Sep;2(9):e350-1. doi: 10.1016/S2352-3026(15)00158-1. Epub 2015 Sep 2. No abstract available.

PMID:
26685766
12.

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment.

Mian SA, Rouault-Pierre K, Smith AE, Seidl T, Pizzitola I, Kizilors A, Kulasekararaj AG, Bonnet D, Mufti GJ.

Nat Commun. 2015 Dec 8;6:10004. doi: 10.1038/ncomms10004.

13.

Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.

Mufti GJ, Kulasekararaj AG, Marsh JC.

N Engl J Med. 2015 Oct 22;373(17):1674-5. doi: 10.1056/NEJMc1509703. No abstract available.

PMID:
26488705
14.

Tissue Iron Distribution Assessed by MRI in Patients with Iron Loading Anemias.

Gutiérrez L, House MJ, Vasavda N, Drašar E, Gonzalez-Gascon Y Marin I, Kulasekararaj AG, St Pierre TG, Thein SL.

PLoS One. 2015 Sep 25;10(9):e0139220. doi: 10.1371/journal.pone.0139220. eCollection 2015.

15.

Chronic relapsing remitting Sweet syndrome--a harbinger of myelodysplastic syndrome.

Kulasekararaj AG, Kordasti S, Basu T, Salisbury JR, Mufti GJ, du Vivier AW.

Br J Haematol. 2015 Sep;170(5):649-56. doi: 10.1111/bjh.13485. Epub 2015 May 12.

PMID:
25962438
16.

High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).

Mohamedali AM, Gäken J, Ahmed M, Malik F, Smith AE, Best S, Mian S, Gaymes T, Ireland R, Kulasekararaj AG, Mufti GJ.

Leukemia. 2015 Sep;29(9):1928-38. doi: 10.1038/leu.2015.110. Epub 2015 May 6.

PMID:
25943179
17.

Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role.

Bart-Smith EE, Kordasti S, Kulasekararaj AG, Richardson D, Mufti GJ, Marsh JC.

AIDS. 2014 Nov 28;28(18):2786-8. doi: 10.1097/QAD.0000000000000504.

PMID:
25333665
18.

Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.

Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S, Gaken J, Czepulkowski B, Marsh JC, Mufti GJ.

Blood. 2014 Oct 23;124(17):2698-704. doi: 10.1182/blood-2014-05-574889. Epub 2014 Aug 18.

19.

Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.

Dufour C, Pillon M, Passweg J, Socié G, Bacigalupo A, Franceschetto G, Carraro E, Oneto R, Risitano AM, Peffault de Latour R, Tichelli A, Rovo A, Peters C, Hoechsmann B, Samarasinghe S, Kulasekararaj AG, Schrezenmeier H, Aljurf M, Marsh J.

Haematologica. 2014 Oct;99(10):1574-81. doi: 10.3324/haematol.2014.106096. Epub 2014 Aug 1.

20.

Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, de Lavallade H, Kenyon M, Pagliuca A, Mufti GJ, Marsh JC.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1711-6. doi: 10.1016/j.bbmt.2014.06.028. Epub 2014 Jul 10.

21.

Management of the refractory aplastic anemia patient: what are the options?

Marsh JC, Kulasekararaj AG.

Hematology Am Soc Hematol Educ Program. 2013;2013:87-94. doi: 10.1182/asheducation-2013.1.87. Review.

PMID:
24319168
22.

Haematopoietic stem cell transplantation for acquired aplastic anaemia.

Young ME, Potter V, Kulasekararaj AG, Mufti GJ, Marsh JC.

Curr Opin Hematol. 2013 Nov;20(6):515-20. doi: 10.1097/MOH.0b013e328365af83. Review.

PMID:
24104412
23.

Management of the refractory aplastic anemia patient: what are the options?

Marsh JC, Kulasekararaj AG.

Blood. 2013 Nov 21;122(22):3561-7. doi: 10.1182/blood-2013-05-498279. Epub 2013 Sep 19. Review.

24.

Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.

Kulasekararaj AG, Mohamedali AM, Mufti GJ.

Br J Haematol. 2013 Sep;162(5):587-605. doi: 10.1111/bjh.12435. Epub 2013 Jul 19. Review.

PMID:
23869491
25.

Bilateral retinal vasculopathy associated with autosomal dominant dyskeratosis congenita.

Vaz-Pereira S, Pacheco PA, Gandhi S, Kulasekararaj AG, Marsh JC, Pal B, Mufti GJ.

Eur J Ophthalmol. 2013 Sep-Oct;23(5):772-5. doi: 10.5301/ejo.5000297. Epub 2013 May 3.

PMID:
23661544
26.

Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.

Gandhi S, Kulasekararaj AG, Mufti GJ, Marsh JC.

Int J Hematol. 2013 May;97(5):573-80. doi: 10.1007/s12185-013-1333-9. Epub 2013 Apr 30. Review.

PMID:
23632948
27.

Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.

Mian SA, Smith AE, Kulasekararaj AG, Kizilors A, Mohamedali AM, Lea NC, Mitsopoulos K, Ford K, Nasser E, Seidl T, Mufti GJ.

Haematologica. 2013 Jul;98(7):1058-66. doi: 10.3324/haematol.2012.075325. Epub 2013 Jan 8.

28.

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, Gäken J, Pennaneach C, Ireland R, Czepulkowski B, Pomplun S, Marsh JC, Mufti GJ.

Br J Haematol. 2013 Mar;160(5):660-72. doi: 10.1111/bjh.12203. Epub 2013 Jan 9.

PMID:
23297687
29.

Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.

Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21.

30.

The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.

Costantini B, Kordasti SY, Kulasekararaj AG, Jiang J, Seidl T, Abellan PP, Mohamedali A, Thomas NS, Farzaneh F, Mufti GJ.

Haematologica. 2013 Aug;98(8):1196-205. doi: 10.3324/haematol.2012.074823. Epub 2012 Dec 14.

31.

SnapShot: Acute myeloid leukemia.

Zeisig BB, Kulasekararaj AG, Mufti GJ, So CW.

Cancer Cell. 2012 Nov 13;22(5):698-698.e1. doi: 10.1016/j.ccr.2012.10.017. No abstract available.

32.

The non-transplant treatment of myelodysplastic syndromes-what's on the horizon?

Kulasekararaj AG, Mufti GJ.

Semin Hematol. 2012 Oct;49(4):350-60. doi: 10.1053/j.seminhematol.2012.07.005. Review.

PMID:
23079065
33.

Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.

Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP.

Blood. 2012 Jun 21;119(25):6109-17. doi: 10.1182/blood-2011-12-397620. Epub 2012 May 2.

34.

A functional assay for microRNA target identification and validation.

Gäken J, Mohamedali AM, Jiang J, Malik F, Stangl D, Smith AE, Chronis C, Kulasekararaj AG, Thomas NS, Farzaneh F, Tavassoli M, Mufti GJ.

Nucleic Acids Res. 2012 May;40(10):e75. doi: 10.1093/nar/gks145. Epub 2012 Feb 9.

35.

Functional characterization of CD4+ T cells in aplastic anemia.

Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, Abellan PP, Veen C, Costantini B, Kulasekararaj AG, Benson-Quarm N, Seidl T, Mian SA, Farzaneh F, Mufti GJ.

Blood. 2012 Mar 1;119(9):2033-43. doi: 10.1182/blood-2011-08-368308. Epub 2011 Dec 2.

36.

Portacaths are safe for long-term regular blood transfusion in children with sickle cell anaemia.

Bartram JL, O'Driscoll S, Kulasekararaj AG, Height SE, Dick M, Patel S, Rees DC.

Arch Dis Child. 2011 Nov;96(11):1082-4. doi: 10.1136/adc.2009.173856. Epub 2010 Jul 6.

PMID:
20605863

Supplemental Content

Loading ...
Support Center